Evotec DNA Damage Response Spin-Out Aims For First IND-Ready Drug In 2022

 
• By Sten Stovall

Evotec’s chief science officer tells Scrip the German biotech is putting its cancer therapeutic program focused on DNA damage response into a new spin-off that aims to have an IND-ready drug in 2022.

Spin off
Breakpoint Therapeutics will develop DDR therapies discovered internally by Evotec • Source: Shutterstock

More from Business

More from Scrip